Table 2.
Antigen | Antibody source | Number of tumors analyzed | − (%) | +/− (%) | + (%) |
---|---|---|---|---|---|
NSE | H14 clone, Dako (Trappes, France) | 8 | 0 | 0 | 100 |
SYN | SY38 clone, Dako (Trappes, France) | 14 | 0 | 0 | 100 |
NF | 2F11 clone, Dako (Trappes, France) | 14 | 0 | 0 | 100 |
ChgA | Dak A3 clone, Dako (Trappes, France) | 13 | 23 | 8 | 69 |
NeuN | Clone A60, Chemicon, Euromedex (Mundolsheim, France) | 5 | 100 | 0 | 0 |
CD34 | Clone QBEND10, Immunotech (Marseille, France) | 2 | 50 | 0 | 50 |
S100‐P | Biomeda 23/11 (Paris) or Dako (Trappes, France) | 12 | 8 | 17 | 75 |
VIM | V9 clone, Dako (Trappes, France) | 11 | 36 | 36 | 27 |
GFAP | 6F2 clone, Dako (Trappes, France) | 13 | 100 | 0 | 0 |